Sophia Genetics Sa · NASDAQ:SOPH
Sophia Genetics Sa — J.P. Morgan Healthcare Conference January 2024
24 slides from Sophia Genetics Sa's conference presentation, Jan 10, 2024
Slide 1: J.P. Morgan Healthcare Conference January 2024
J.P. Morgan Healthcare Conference January 2024 Jurgi Camblong CEO and Co - Founder at SOPHiA GENETICS
Slide 2: Cautionary notices
Cautionary notices 2 This presentation contains statements that constitute forward - looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy,
Slide 3: The age of data-driven medicine
fT) Explosion of healthcare data . af Advancements in cloud-based computing a Developments in artificial intelligence The age of data-driven medicine | SOPHiA DDM" |" 1] —
Slide 4: Rapid expansion of precision medicine with data at the core
© SOPHiA GENETICS 2024 Rapid expansion of precision medicine with data at the core 4 2012 F o un d a t i o n O n e ® launch Pioneered a centralized approach to pan - cancer NGS with IT expertise 2015 Tempus and Caris emerge 2011 Illumina MiSeq TM launch Initiated the broad adoption of NGS by hospita
Slide 5: We are targeting a sizeable addressable market
© SOPHiA GENETICS 2024 We are targeting a sizeable addressable market 5 Clinical market Generating insights from multimodal data to help Clinicians with screening, early detection, diagnosis, therapy selection, and monitoring $25B BioPharma market Generating insights from multimodal data to help Bio
Slide 6: Industry-leading multimodal capabilities driven by AI makes us the platform of choice
© SOPHiA GENETICS 2024 Industry - leading multimodal capabilities driven by AI makes us the platform of choice for actionable patient insights 6
Slide 7: Underpinned by universal compatibility and a decentralized approach
© SOPHiA GENETICS 2024 Underpinned by universal compatibility and a decentralized approach 7 (1) NPS Score reflects survey results users of SOPHiA DDM TM ’s core genomic module (i.e., SOPHiA DDM for Genomics) only and excludes survey results from users of add - on modules such as Alamut.
Slide 8: FY 2023 highlights
FY 2023 highlights (1) Total customer count reported from the 12 - month period ending November 30, 2023. (2) New signed core genomics customers as of December 31, 2023. (3) Analysis volume reported as of December 31, 2023. Figure includes volumes related to COVID - 19.
Slide 9: Q4 2023 highlights
Q4 2023 highlights (1) New signed core genomics customers as of December 31, 2023. (2) Analysis volume reported as of December 31, 2023. Figure includes volumes related to COVID - 19.
Slide 10: SOPHiA DDM serves oncology and rare disease patients across the patient journey
© SOPHiA GENETICS 2024 SOPHiA DDM TM serves oncology and rare disease patients with a comprehensive portfolio of applications across the patient journey 10
Slide 11: Analysis volume on SOPHiA DDM is growing rapidly across all applications
© SOPHiA GENETICS 2024 Analysis volume on SOPHiA DDM TM is growing rapidly across all applications 11 (1) Year - over - year analysis volume as of December 31, 2023. Analysis volume growth is presented excluding COVID - related volumes.
Slide 12: Platform consumption driving strong revenue growth in 2023 and beyond
© SOPHiA GENETICS 2024 Platform consumption driving strong revenue growth in 2023 and beyond 12 FY results expected to be in line with guidance provided at Q3 earnings: > Reported revenue growth: Full - year growth at or above 30% > Constant currency revenue growth excluding COVID - 19 revenue: Full
Slide 13: SOPHiA DDM's best-in-class HRD application
© SOPHiA GENETICS 2024 SOPHiA DDM TM ’s best - in - class HRD application 13 (1) HRD analysis volume growth and customer counts as of December 31, 2023. other cancer types
Slide 14: Expanding our success in oncology with a world-class application in LBx
© SOPHiA GENETICS 2024 Expanding our success in oncology with a world - class application in LBx 14
Slide 15: Significant momentum in the US market
© SOPHiA GENETICS 2024 Significant momentum in the US market 15
Slide 16: The Clinical and BioPharma flywheel
© SOPHiA GENETICS 2024 16 The Clinical and BioPharma flywheel
Slide 17: Slide 17
Slide 18: Data processed on SOPHiA DDM has exploded over the years
© SOPHiA GENETICS 2024 18 Data processed on SOPHiA DDM TM has exploded over the years (1) Figures represent an estimate of total data processed on SOPHiA DDM TM as of December 31, 2023.
Slide 19: SOPHiA DDM connects multimodal data globally
© SOPHiA GENETICS 2024 SOPHiA DDM TM connects multimodal data globally to enable the age of data - driven medicine 19
Slide 20: But we are not alone in this mission
© SOPHiA GENETICS 2024 But we are not alone in this mission 20
Slide 21: We are committed to achieve profitability over the next 2+ years
© SOPHiA GENETICS 2024 We are committed to achieve profitability over the next 2+ years 21 Backed by a consistent track - record of strong top - and bottom - line improvement 40% YoY IFRS revenue growth in Q3 2023 37% YoY revenue growth constant currency, ex - COVID in Q3 2023 73% Adjusted gross mar
Slide 22: Democratizing Data-Driven Medicine, Together
on. SOPHIA * ee GENETICS” Democratizing Data-Driven Medicine, Together
Slide 23: Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth Excluding COVID-19
© SOPHiA GENETICS 2024 Reconciliation of IFRS Revenue Growth to Constant Current Revenue Growth Excluding COVID - 19 - Related Revenue 23 Q3 2022 Q3 2023 Y - o - Y Growth $1 1 , 648 $1 6 , 303 40% — ( 766) $13,800 $15,537 33% ( 290) ( 16) — — $1 3 , 563 $1 5 , 521 37% (Amounts in USD Thousands) IFRS
Slide 24: Reconciliation of IFRS Financials to Adjusted Financials
Reconciliation of IFRS Financials to Adjusted Financials 24 FY 2022 FY 2023 Q1 Q2 Q3 Q4 Q1 Q2 Q3 $10, 8 6 1 $11, 6 6 7 $11, 6 4 8 $13, 3 8 4 $13, 9 6 6 $15, 0 5 4 $16, 3 0 3 $6,7 10 62% $7,6 20 65% $7,2 93 63% $9,6 31 72% $9,6 94 69% $10, 0 4 7 67% $11, 2 7 3 69% 198 253 304 378 432 496 552 $6,9 08
SOPHiA GENETICS — J.P. Morgan Healthcare Conference January 2024 on 6ix